CTRI/2022/06/043406尚未招募3 期
A randomized, open-label, parallel-group study to evaluate the safety and efficacy of abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in India
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- Pfizer Inc
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(1) Participants must be of 12 years of age or older, at the time of informed consent.
- •(2) Meet all the following AD criteria:
- •(a) Clinical diagnosis of chronic AD (also known as atopic eczema) for at least 1 year prior to Day 1 and has confirmed AD (Hanifin and Rajka criteria of AD).
- •(b) Moderate to severe AD (affected BSA >=10%, IGA >=3, EASI >=16, and PP NRS >=4 at the baseline visit);
- •(c) Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications for at least 4 weeks, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks), or who have required systemic therapies for control of their disease.
- •(3) Negative pregnancy test for females of childbearing potential at Screening. Female participants of childbearing potential must agree to use a highly effective method of contraception for the duration of the active treatment period and for at least 28 days after the last dose of study intervention.
- •(4) Body weight >=25 kg at Baseline.
排除标准
- •(1)Currently have active forms of other inflammatory skin diseases or have evidence of skin conditions (eg, psoriasis, seborrheic dermatitis, lupus).
- •(2) A current or past medical history of conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction or QT interval abnormalities.
- •(3) Have increased risk of developing venous thromboembolism, eg, deep vein thrombosis or pulmonary embolism.
- •(4) Have a history of any lymphoproliferative disorder such as EBV related lymphoproliferative disorder, history of lymphoma, leukemia, or signs or symptoms suggestive of current lymphatic or lymphoid disease.
- •(5) Past history or active infection with Mycobacterium TB, disseminated herpes zoster or disseminated herpes simplex, HIV, Hepatitis B, or Hepatitis C.
- •(6) Have any malignancies or have a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ
- •(7) Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigatorâ??s judgement, make the participant inappropriate for the study.
- •(8) Prior treatment with systemic JAK inhibitors.
- •(9) Participants who are vaccinated with live attenuated vaccine within the 6 weeks prior to the first dose of abrocitinib or who are expected to be vaccinated with these vaccines during treatment or during the 6 weeks following discontinuation of abrocitinib.
- •(10) Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication.
- •(11) Any of the following abnormalities in clinical laboratory tests at Screening:
- •(a) Absolute neutrophil count of <1.0 Ã? 109/L ( <1000/mm3);
- •(b) Platelet count of <150 Ã? 109/L ( <150,000/mm3);
- •(c) Absolute lymphocyte count of <0.50 Ã? 109/L ( <500/mm3);
- •(d) Estimated Creatinine Clearance ï?¼60 mL/min using the Cockcroftâ??Gault method;
- •(e) AST or ALT values >2 times the ULN;
- •(f) TBili >=1.5 times the ULN;
- •(12) Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use highly effective contraception consistently and correctly for the entire duration of the study and for at least 28 days after the last dose of study intervention.
研究者
相似试验
进行中（未招募）
不适用
A randomized, open-label, parallel-group study to investigate blood concentrations, safety and tolerability of 2 ointment formulations of ASM981 in adult patients with atopic dermatitis treated topically for 2 weeks - A2308Atopic dermatitis (atopic eczema)EUCTR2004-003798-94-ATovartis Pharma Services AG20
尚未招募
不适用
A randomized, open-label, parallel-group study to evaluate the efficacy of dry chemical mopping in adults with mild to moderate atopic dermatitis.Atopic dermatitis of mild to moderate severityJPRN-UMIN000045727Mie University, Graduate School of Medicine42
招募中
1 期
To evluate the safety profile of NR-INF-02CTRI/2018/02/011766atrural Remedies Private Limited
已完成
不适用
A randomized, open-label, parallel group study to evaluate the efficacy and safety of the oral administration of Bifidobacterium animalis subsp. lactis LKM512 in patients with atopic dermatitisAtopic dermatitisJPRN-UMIN000005695Kyodo Milk Industry Co. Ltd.50
进行中（未招募）
3 期
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL).on-Hodgkin's LymphomaNon-Hodgkin's LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12610000445077Cephalon Inc436